You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEnalkiren
Accession NumberDB03395  (EXPT03298)
TypeSmall Molecule
GroupsExperimental
DescriptionNot Available
Structure
Thumb
SynonymsNot Available
External Identifiers
  • A-64662
  • ABBOTT-64662
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ENALKIRENNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII0U7YZ42Z47
CAS number113082-98-7
WeightAverage: 656.8557
Monoisotopic: 656.426133554
Chemical FormulaC35H56N6O6
InChI KeyKQXVERRYBYGQJZ-WRPDIKACSA-N
InChI
InChI=1S/C35H56N6O6/c1-22(2)15-30(42)32(44)27(16-23-9-7-6-8-10-23)40-34(46)29(18-25-20-37-21-38-25)41-33(45)28(39-31(43)19-35(3,4)36)17-24-11-13-26(47-5)14-12-24/h11-14,20-23,27-30,32,42,44H,6-10,15-19,36H2,1-5H3,(H,37,38)(H,39,43)(H,40,46)(H,41,45)/t27-,28-,29-,30-,32+/m0/s1
IUPAC Name
3-amino-N-[(1S)-1-{[(1S)-1-{[(2S,3R,4S)-1-cyclohexyl-3,4-dihydroxy-6-methylheptan-2-yl]carbamoyl}-2-(1H-imidazol-5-yl)ethyl]carbamoyl}-2-(4-methoxyphenyl)ethyl]-3-methylbutanamide
SMILES
COC1=CC=C(C[[email protected]](NC(=O)CC(C)(C)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC2CCCCC2)[C@@H](O)[C@@H](O)CC(C)C)C=C1
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
ReninProteinunknown
inhibitor
HumanP00797 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Enalkiren.Approved, Investigational
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Enalkiren.Approved, Investigational
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Enalkiren.Approved, Illicit, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Enalkiren.Experimental
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Enalkiren.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Enalkiren.Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Enalkiren.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Enalkiren.Approved
BoceprevirThe serum concentration of Enalkiren can be decreased when it is combined with Boceprevir.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Enalkiren.Approved, Investigational
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Enalkiren.Approved
CarbamazepineThe metabolism of Enalkiren can be increased when combined with Carbamazepine.Approved, Investigational
ChlorotrianiseneThe serum concentration of Chlorotrianisene can be decreased when it is combined with Enalkiren.Withdrawn
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Enalkiren.Approved, Investigational, Withdrawn
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with Enalkiren.Approved
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Enalkiren.Approved, Vet Approved
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Enalkiren.Approved
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Enalkiren.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Enalkiren is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Enalkiren.Approved, Investigational, Vet Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Enalkiren.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Enalkiren.Approved
DienestrolThe serum concentration of Dienestrol can be decreased when it is combined with Enalkiren.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Enalkiren.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Enalkiren.Approved
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Enalkiren.Approved
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Enalkiren.Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Enalkiren.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Enalkiren.Approved
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Enalkiren.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Enalkiren.Approved, Investigational
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Enalkiren.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Enalkiren.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Enalkiren.Approved
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Enalkiren.Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Enalkiren.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Enalkiren.Approved
Estrogens, esterifiedThe serum concentration of Estrogens, esterified can be decreased when it is combined with Enalkiren.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Enalkiren.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Enalkiren.Approved
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Enalkiren.Approved
GarlicThe serum concentration of Enalkiren can be decreased when it is combined with Garlic.Approved
HexestrolThe serum concentration of Hexestrol can be decreased when it is combined with Enalkiren.Withdrawn
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Enalkiren.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Enalkiren.Approved, Investigational
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Enalkiren.Approved
MethallenestrilThe serum concentration of Methallenestril can be decreased when it is combined with Enalkiren.Experimental
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Enalkiren.Approved, Illicit
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Enalkiren.Approved
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Enalkiren.Approved, Withdrawn
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Enalkiren.Approved
OpipramolThe serum concentration of Opipramol can be increased when it is combined with Enalkiren.Investigational
PethidineThe risk or severity of adverse effects can be increased when Enalkiren is combined with Pethidine.Approved
PimozideThe serum concentration of Pimozide can be increased when it is combined with Enalkiren.Approved
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Enalkiren.Approved
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Enalkiren.Approved
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Enalkiren.Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Enalkiren.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Enalkiren.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Enalkiren.Approved
St. John's WortThe metabolism of Enalkiren can be increased when combined with St. John's Wort.Nutraceutical
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Enalkiren.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Enalkiren.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Enalkiren is combined with Temsirolimus.Approved
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Enalkiren.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Enalkiren.Approved
TipranavirThe serum concentration of Enalkiren can be decreased when it is combined with Tipranavir.Approved, Investigational
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Enalkiren.Approved
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Enalkiren.Approved
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with Enalkiren.Approved, Investigational
VerapamilThe metabolism of Verapamil can be decreased when combined with Enalkiren.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Enalkiren.Approved
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Glassman HN, Kleinert HD, Boger RS, Moyse DM, Griffiths AN, Luther RR: Clinical pharmacology of enalkiren, a novel, dipeptide renin inhibitor. J Cardiovasc Pharmacol. 1990;16 Suppl 4:S76-81. [PubMed:1705633 ]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.6463
Blood Brain Barrier-0.9672
Caco-2 permeable-0.7867
P-glycoprotein substrateSubstrate0.8135
P-glycoprotein inhibitor INon-inhibitor0.7852
P-glycoprotein inhibitor IINon-inhibitor0.7862
Renal organic cation transporterNon-inhibitor0.8892
CYP450 2C9 substrateNon-substrate0.7924
CYP450 2D6 substrateNon-substrate0.7498
CYP450 3A4 substrateSubstrate0.6589
CYP450 1A2 substrateNon-inhibitor0.866
CYP450 2C9 inhibitorNon-inhibitor0.7568
CYP450 2D6 inhibitorNon-inhibitor0.8521
CYP450 2C19 inhibitorNon-inhibitor0.6809
CYP450 3A4 inhibitorNon-inhibitor0.5122
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6567
Ames testNon AMES toxic0.7827
CarcinogenicityNon-carcinogens0.9252
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6931 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9939
hERG inhibition (predictor II)Non-inhibitor0.6604
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0122 mg/mLALOGPS
logP2.47ALOGPS
logP1.75ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)12.03ChemAxon
pKa (Strongest Basic)9.58ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count7ChemAxon
Polar Surface Area191.69 Å2ChemAxon
Rotatable Bond Count18ChemAxon
Refractivity180.16 m3·mol-1ChemAxon
Polarizability72.65 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as hybrid peptides. These are compounds containing at least two different types of amino acids (alpha, beta, gamma, delta) linked to each other through a peptide bond.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentHybrid peptides
Alternative Parents
Substituents
  • Hybrid peptide
  • N-acyl-alpha amino acid or derivatives
  • Alpha-amino acid amide
  • Beta amino acid or derivatives
  • Phenylpropylamine
  • Amphetamine or derivatives
  • N-substituted-alpha-amino acid
  • Methoxybenzene
  • Phenol ether
  • Anisole
  • Alkyl aryl ether
  • Fatty acyl
  • Benzenoid
  • N-acyl-amine
  • Fatty amide
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Secondary carboxylic acid amide
  • Secondary alcohol
  • Carboxamide group
  • 1,2-diol
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Primary aliphatic amine
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Receptor binding
Specific Function:
Renin is a highly specific endopeptidase, whose only known function is to generate angiotensin I from angiotensinogen in the plasma, initiating a cascade of reactions that produce an elevation of blood pressure and increased sodium retention by the kidney.
Gene Name:
REN
Uniprot ID:
P00797
Molecular Weight:
45057.125 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Glassman HN, Kleinert HD, Boger RS, Moyse DM, Griffiths AN, Luther RR: Clinical pharmacology of enalkiren, a novel, dipeptide renin inhibitor. J Cardiovasc Pharmacol. 1990;16 Suppl 4:S76-81. [PubMed:1705633 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23